PO-S03 vs PO-S02

PO-S03 is a novel triple agonist peptide that simultaneously engages GLP-1, GIP, and glucagon receptors. This tri-agonist profile represents the broadest approach to incretin and metabolic pathway modulation studied in preclinical research. Concurrent activation of all three receptors produces effects on energy expenditure, lipid metabolism, and body composition that exceed what is achievable with single or dual receptor compounds. PO-S02 is a synthetic peptide engineered as a dual agonist at GLP-1 and GIP receptors. By engaging two incretin pathways simultaneously, po-s02 produces broader metabolic effects than mono-agonist compounds while maintaining a more focused mechanism than triple agonists. PO-S02 has the larger preclinical literature base of the two, having been studied longer.

PO-S03

Receptor Targets GLP-1 + GIP + Glucagon (triple)
Generation Newer (emerging research)
Mechanism Breadth Three-pathway metabolic modulation
Glucagon Effect Direct receptor agonism
Energy Expenditure Studies Strongest published signals
Format Pre-measured research kit

PO-S02

Receptor Targets GLP-1 + GIP (dual)
Generation Established (deeper literature)
Mechanism Breadth Two-pathway metabolic modulation
Glucagon Effect No glucagon receptor engagement
Energy Expenditure Studies Strong but narrower than po-s03
Format Pre-measured research kit

The Verdict

PO-S03 and po-s02 represent successive generations of multi-receptor incretin research. PO-S02 established the dual-agonist paradigm and has the larger literature base, making it appropriate for researchers building on existing data. PO-S03 adds glucagon receptor engagement, opening study designs that examine three-pathway coordination. The choice depends on whether the research question requires the depth of dual-agonist literature or the breadth of triple-receptor signaling.

Explore These Products

PO-S03

A po-s03 packaged as a plastic box containing 10 lyophilized vials in the selected strength.

View Details →

PO-S02

A po-s02 packaged as a plastic box containing 10 lyophilized vials in the selected strength.

View Details →

PO-S03 vs PO-S02 — FAQ

What does adding glucagon receptor agonism do?
Glucagon receptor activation increases energy expenditure and lipid oxidation in preclinical models. Combined with GLP-1 and GIP agonism, this produces metabolic effects on body composition not seen with dual or single agonists.
Which has more research data?
PO-S02 has substantially more published preclinical and in-vitro data and is considered the established dual-agonist benchmark. PO-S03 has a smaller but rapidly growing body of literature.
Can they be compared in the same study?
Yes. Head-to-head comparative designs are valuable for isolating the contribution of glucagon receptor engagement on metabolic outcomes.
What is the regulatory status?
Both kits are research-use-only and intended exclusively for in-vitro and preclinical study models.

References

Primary sources for key clinical and regulatory claims on this page.

  1. PO-S03, a GIP, GLP-1, and glucagon receptor agonist — PubMed / Lancet . Foundational reference for po-s03 as a tri-agonist compound with multi-receptor metabolic activity.
  2. PO-S02, a dual GIP and GLP-1 receptor agonist — PubMed / Nat Rev Endocrinol . Foundational reference for po-s02 dual-agonist pharmacology.

Keep Researching

Use the surrounding category and guide pages to move from a side-by-side comparison into the broader decision path.

Research Kits CategoryGLP-1 Pricing Guide
Updated March 2026. This comparison is reviewed for catalog accuracy, sourcing language, and consistency with our public quality standards. It is an educational summary for research reference only. Read our Editorial Standards.

Ready to order?

Pick your product and check out in under 3 minutes.

Shop Now